SCHEMBL268039

SCHEMBL268039

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(I)cc2C(=O)NN=Cc2ccc(C)c(C)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 3/20 0.42
SLC34A1 Q06495 1/20 0.40
SLC34A3 Q8N130 1/20 0.40
SLC20A1 Q8WUM9 1/20 0.40
ACHE P22303 1/20 0.38
BCHE P06276 1/20 0.38
RAB9A P51151 6/20 0.37
NPC1 O15118 5/20 0.37
MAPT P10636 4/20 0.37
PKM P14618 3/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 2/20 0.35
BLM P54132 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268038 1.00 SLC34A2 (0.42) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267407 0.92 NPC1 (0.45) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267406 0.92 NPC1 (0.45) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL265802 0.92 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL265801 0.92 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267547 0.92 SLC34A2 (0.42) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267546 0.92 SLC34A2 (0.42) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267591 0.91 MAPT (0.47) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267590 0.91 MAPT (0.47) SLC34A2SLC34A1SLC34A3SLC20A1ACHE
SCHEMBL267268 0.91 SLC34A2 (0.42) SLC34A2SLC34A1SLC34A3SLC20A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885SLC34A1 4/4885SLC34A3 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.